Research programme: cannabidiol conjugated anti-cancer therapeutics - Diverse Biotech
Latest Information Update: 28 Dec 2023
At a glance
- Originator Diverse Biotech
- Class Antineoplastics; Cannabinoids
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Basal cell cancer; Glioblastoma; Pancreatic cancer
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Basal-cell-cancer in USA
- 28 Dec 2023 No recent reports of development identified for preclinical development in Glioblastoma in USA
- 28 Dec 2023 No recent reports of development identified for preclinical development in Pancreatic-cancer in USA